Centrient Pharmaceuticals* publishes 2024 ESG Report, reaffirming commitment to sustainable and responsible manufacturing of medicines

• 1.57 billion patient treatments enabled in 2024 – significant progress toward 2030 target of 2 billion
• 8% reduction in Scope 1 and 2 emissions; 13% reduction in water usage vs 2021 baseline
• Fifth consecutive Gold EcoVadis sustainability rating – ranking among top 5% of global companies

Rotterdam, Netherlands, 30 June 2025 

Centrient Pharmaceuticals today published its 2024 Environmental, Social and Governance (ESG) Report, showcasing substantial progress toward the company’s ESG Ambition 2021–2030. The report reflects the company’s ongoing commitment to operating responsibly while ensuring global access to essential medicines.

“Our commitment to ESG reflects our responsibility to the world around us,” said Rex Clements, CEO of Centrient. “Our ability to operate responsibly, reduce our environmental footprint, and ensure patients have access to the medicines they need means we are committed to doing what's right, every step of the way. We’re proud of what we’ve achieved in 2024, and we’re driven to doing even more.”

Environmental Highlights

In 2024, Centrient reduced its Scope 1 and 2 greenhouse gas emissions by 8% in 2024 compared with its 2022 baseline. This reduction was achieved through targeted initiatives across key sites, such as transitioning from fuel oil to cleaner natural gas, increasing the share of renewable electricity, and renovating chillers to minimise refrigerant gas loss.

The company’s near-term climate targets were also validated by the Science Based Targets initiative (SBTi), reinforcing the credibility of its emissions reduction strategy.

On water management, Centrient surpassed its 10% reduction target by cutting total water consumption by 13% compared with 2021. Key actions included increased water recycling, a full-site water audit in Toansa, India, and process optimizations at manufacturing sites in China and Mexico. With water scarcity and quality emerging as critical global challenges, Centrient is taking concrete steps to reduce its footprint and protect water resources in the communities where it operates.

In Spain, the Santa Perpètua facility received the British Standards Institute's (BSI) Minimized Risk for Antimicrobial Resistance (AMR) Kitemark™ certificate, recognizing its leadership in producing antibiotics with strict environmental safeguards that help combat AMR.

Social responsibility and patient access

In 2024, Centrient’s voluntary attrition rate stood at 6%, outperforming its target of 8%. The company remains focused on maintaining low attrition and identifying areas for improvement.

On the access front, Centrient joined the Critical Medicines Alliance—an EU-led initiative focused on building resilient supply chains for essential medicines across Europe.

Governance and industry recognition

Centrient earned a Gold sustainability rating from EcoVadis for the fifth consecutive year. This places the company among the top 5% of all companies assessed globally, and in the top 4% of companies assessed in the manufacturing of basic pharmaceutical products and pharmaceutical preparations category.

Read Centrient's 2024 ESG Report in full: here

About Centrient Pharmaceuticals

Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. We are a pharmaceutical company with a clear Purpose: to improve lives through innovative and sustainable manufacturing of medicines - saving the lives of millions of people around the world annually. Regarding our portfolio, we produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as finished dosage forms (FDFs). Centrient Pharmaceuticals is a Board Member of the AMR Industry Alliance and a long-time advocate for industry responsibility in manufacturing. 

For more information, please visit www.centrient.com, www.linkedin.com/company/centrient or contact Centrient Pharmaceuticals Global Communications and ESG Director, Neil Moorhouse. E-Mail: neil.moorhouse@centrient.com.

*(1) “Centrient Pharmaceuticals”, “Centrient” in this content are sometimes used for convenience where references are made to Centrient International Pharmaceuticals B.V, and or one or more of its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Centrient Pharmaceuticals International B.V. and or one or more of its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. “Subsidiaries”, “Centrient subsidiaries” and “Centrient companies” as used in this content refer to entities over which Centrient Pharmaceuticals International B.V. either directly or indirectly has control. The term “Centrient interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Centrient Pharmaceuticals International B.V. in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.